A new treatment option is expected to emerge in the field of colorectal cancer later this year.

According to industry sources, the final review is underway for the approval of Fruzaqla (fruquintinib), which was designated as a Global Innovative products on Fast Track (GIFT) by the Ministry of Food and Drug Safety in November last year.

Fruzaqla was designated as an orphan drug in Korea in February and was granted priority review by the U.S. FDA in May last year and received final approval in November of the same year.

In addition to the U.S. FDA approval in November last year, the drug recently received final approval from the European Commission.

Fruzaqla i